K2 Principal Fund, L.P. Biomarin Pharmaceutical Inc Transaction History
K2 Principal Fund, L.P.
- $307 Million
- Q4 2024
A detailed history of K2 Principal Fund, L.P. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, K2 Principal Fund, L.P. holds 23,000 shares of BMRN stock, worth $1.59 Million. This represents 0.49% of its overall portfolio holdings.
Number of Shares
23,000Holding current value
$1.59 Million% of portfolio
0.49%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding BMRN
# of Institutions
626Shares Held
183MCall Options Held
2MPut Options Held
1.67M-
Black Rock Inc. New York, NY22.7MShares$1.57 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.4MShares$1.34 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.2MShares$1.26 Billion0.94% of portfolio
-
Dodge & Cox San Francisco, CA14.7MShares$1.02 Billion0.61% of portfolio
-
Capital Research Global Investors Los Angeles, CA13MShares$897 Million0.18% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $12.8B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...